Lijnen H R, Carmeliet P, Bouché A, Moons L, Ploplis V A, Plow E F, Collen D
Center for Molecular and Vascular Biology, University of Leuven, Belgium.
Blood. 1996 Aug 1;88(3):870-6.
Homozygous plasminogen-deficient (Plg-/-) mice had a significantly reduced thrombolytic capacity toward intravenously injected 125I-fibrin labeled plasma clots prepared from Plg-/- murine plasma (9% +/- 3% lysis after 8 hours; (mean +/- SEM, n = 6), as compared with 82% +/- 8% in wild-type mice; P < .0001). Bolus injection of 1 mg purified murine plasminogen in 10- to 17-week-old Plg-/- mice increased the plasminogen antigen and activity levels at 8 hours to normal levels (130 +/- 5 micrograms/mL). Plasminogen administration was associated with significant restoration of thrombolytic potential (64% +/- 7% spontaneous clot lysis; P < .0001 versus lysis without plasminogen injection). Bolus injection of 1 mg plasminogen in homozygous tissue-type plasminogen activator-deficient (t-PA-/-) mice doubled the plasminogen antigen and activity levels after 8 hours and increased 125I-fibrin clot lysis at 8 hours from 13% +/- 3% to 34% +/- 5% (P = .008). Fibrinogen, t-PA antigen and alpha 2-antiplasmin activity levels after 8 hours were not significantly different in the groups with or without plasminogen injection. Injection of plasminogen induced a variable increase (on average 7- to 10-fold) of PAI-1, but no correlation with the extent of spontaneous clot lysis was observed. Histopathologic examination at the end of the experiments revealed that fibrin deposition in the liver of Plg-/- mice was slightly reduced 8 hours after bolus plasminogen injection (P = .007) and markedly reduced after 24 hours (P < .0001). Plasminogen antigen levels in liver extracts were comparable with those found in wild-type mice at 8 hours (130 +/- 20 versus 110 +/- 15 ng/mg protein) and decreased to 25 +/- 3.2 ng/mg protein at 24 hours. Thus, restoration of normal plasminogen levels in Plg-/- mice normalized the thrombolytic potential toward experimentally induced pulmonary emboli, and resulted in removal of endogenous fibrin deposits within 24 hours.
纯合子纤溶酶原缺陷(Plg-/-)小鼠对静脉注射的由Plg-/-小鼠血浆制备的125I-纤维蛋白标记血浆凝块的溶栓能力显著降低(8小时后溶解率为9%±3%;(平均值±标准误,n = 6),而野生型小鼠为82%±8%;P <.0001)。对10至17周龄的Plg-/-小鼠静脉推注1 mg纯化的小鼠纤溶酶原,可使8小时时的纤溶酶原抗原和活性水平恢复至正常水平(130±5微克/毫升)。给予纤溶酶原与溶栓潜力的显著恢复相关(自发凝块溶解率为64%±7%;与未注射纤溶酶原的溶解情况相比,P <.0001)。对纯合子组织型纤溶酶原激活物缺陷(t-PA-/-)小鼠静脉推注1 mg纤溶酶原,8小时后纤溶酶原抗原和活性水平加倍,8小时时125I-纤维蛋白凝块溶解率从13%±3%增加至34%±5%(P =.008)。注射或未注射纤溶酶原的组在8小时后的纤维蛋白原、t-PA抗原和α2-抗纤溶酶活性水平无显著差异。注射纤溶酶原可使PAI-1有不同程度的升高(平均升高7至10倍),但未观察到与自发凝块溶解程度的相关性。实验结束时的组织病理学检查显示,在静脉推注纤溶酶原8小时后,Plg-/-小鼠肝脏中的纤维蛋白沉积略有减少(P =.007),24小时后显著减少(P <.0001)。肝脏提取物中的纤溶酶原抗原水平在8小时时与野生型小鼠相当(130±20对110±15纳克/毫克蛋白),24小时时降至25±3.2纳克/毫克蛋白。因此,恢复Plg-/-小鼠的正常纤溶酶原水平可使对实验性诱导的肺栓塞的溶栓潜力正常化,并在24小时内导致内源性纤维蛋白沉积物的清除。